|
RAB23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.44249065417534E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62858615482264E-12 |
| Normal-vs-Stage2 |
1.62492241884138E-12 |
| Normal-vs-Stage3 |
1.71618275146557E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
8.268100E-02 |
| Stage1-vs-Stage3 |
4.002200E-01 |
| Stage1-vs-Stage4 |
6.100000E-03 |
| Stage2-vs-Stage3 |
3.025700E-02 |
| Stage2-vs-Stage4 |
6.966200E-01 |
| Stage3-vs-Stage4 |
2.580900E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62925228863742E-12 |
| Normal-vs-AfricanAmerican |
2.13029999973635E-07 |
| Normal-vs-Asian |
1.29896093881143E-13 |
| Caucasian-vs-AfricanAmerican |
4.172000E-01 |
| Caucasian-vs-Asian |
9.029400E-01 |
| AfricanAmerican-vs-Asian |
4.758600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.62825308791525E-12 |
| Male-vs-Female |
3.434400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.66133814775094E-15 |
| Normal-vs-Age(41-60Yrs) |
1.63580260448271E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.785900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.194000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.028000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.249200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.553800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.886800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.095000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.170400E-01 |
| Classical-VS-Follicular |
8.26780000000582E-05 |
| Classical-VS-Other |
5.369400E-01 |
| Classical-VS-Normal |
1.7812418207086E-12 |
| Tall-VS-Follicular |
6.026900E-04 |
| Tall-VS-Other |
2.601600E-01 |
| Tall-VS-Normal |
1.16959997242816E-10 |
| Follicular-VS-Other |
5.178800E-01 |
| Follicular-VS-Normal |
<1E-12 |
| Other-VS-Normal |
1.962140E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62458935193399E-12 |
| Normal-vs-N1 |
9.79216707719388E-14 |
| N0-vs-N1 |
4.330000E-01 |
|
|
